OASM News

Pricing pressure continued this week as only one company was able to price in or above its range. Five IPOs raised $1.2 billion this week, including one of the most highly-anticipated IPOs of 2015. However, it was a global print packaging manufacturer that had the best IPO. Two biotechs and a REIT specializing in farmland went public this week as well. One...read more

Oasmia Pharmaceutical, which is developing new formulations of existing chemotherapy drugs for use in humans and dogs, raised $9 million by offering 2.3 million ADSs at $4.06, below the range of $4.70 to $6.70. The offering also included 1.1 million warrants with an exercise price of $4.06 per ADS. The company originally filed to offer ADSs at $5.25-8.25. It currently trades on the...read more

Oasmia Pharmaceutical, which is developing formulations of widely-used cancer drugs for humans and dogs, lowered the proposed deal size for its upcoming IPO on Monday.  The Uppsala, Sweden-based company decreased the proposed maximum aggregate offering from $23 million to $15 million. At this new maximum, Oasmia Pharmaceutical will raise -35% less in proceeds than...read more

A still fragile US IPO market will look to continue to find its footing this week. Companies have experienced significant pricing pressure in the last few weeks, with 11 out of the last 13 IPOs pricing below the range. Next week, a highly-anticipated premier luxury brand, a specialty packaging company, and two biotechs plan to go public. Three other companies are...read more